Rusfertide Sales Forecast and Market Size Analysis 2020-2025 & 2026-2034
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Rusfertide Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of rusfertide (PTG-300) across polycythemia vera (PV), haemochromatosis and other potential indications involving iron dysregulation. The analysis covers the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.
The report examines rusfertide's clinical development, regulatory progress, market potential, competitive positioning, pricing outlook and forecast sales through 2034. It also evaluates the factors expected to influence physician adoption, patient access and commercial performance following potential regulatory approval.
Key Factors Driving Rusfertide Market Growth
Rusfertide Drug and Clinical Overview
Rusfertide is being developed by Protagonist Therapeutics, with Takeda positioned to support its potential commercialization. The therapy is administered as a once-weekly subcutaneous injection and is intended to maintain hematocrit below 45%, reduce therapeutic phlebotomy requirements and mitigate iron deficiency associated with repeated procedures.
Clinical evidence generated to date supports rusfertide's potential role in the long-term management of polycythemia vera. The report evaluates its efficacy, safety, dosage and administration, clinical trial status, expected treatment duration and differentiation from current and emerging therapies.
Scope of the Rusfertide Market Report
Rusfertide Market Potential and Competitive Intelligence
The report assesses rusfertide's projected market size, peak sales potential and expected uptake across key geographies. It compares the product's clinical profile with existing treatments and pipeline competitors, identifying potential strengths, limitations, growth barriers and commercial opportunities.
Competitive intelligence includes the number and status of therapies in development, expected launch dates, clinical differentiation and the potential effect of emerging products on rusfertide's market share. The analysis also considers physician prescribing behavior, patient eligibility, reimbursement conditions and regional access dynamics.
Key Questions Addressed
The report offers strategic insights for pharmaceutical companies, investors, healthcare stakeholders and portfolio decision-makers evaluating the future of rusfertide in polycythemia vera, haemochromatosis and other potential indications associated with iron dysregulation.
Key Topics Covered
1. Report Introduction
2. Rusfertide Overview in potential indication like Polycythaemia vera and Haemochromatosis
2.1. Product Detail
2.2. Rusfertide Clinical Development
2.2.1. Rusfertide Clinical studies
2.2.2. Rusfertide Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Rusfertide Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Rusfertide Therapies)
5. Rusfertide Market Assessment
5.1. Rusfertide Market Outlook in potential indications
5.2. 7MM Analysis
5.2.1. Rusfertide Market Size in the 7MM for potential indications
5.3. Country-wise Market Analysis
5.3.1. Rusfertide Market Size in the United States for potential indications
5.3.2. Rusfertide Market Size in Germany for potential indications
5.3.3. Rusfertide Market Size in France for potential indications
5.3.4. Rusfertide Market Size in Italy for potential indications
5.3.5. Rusfertide Market Size in Spain for potential indications
5.3.6. Rusfertide Market Size in the United Kingdom for potential indications
5.3.7. Rusfertide Market Size in Japan for potential indications
6. Rusfertide SWOT Analysis
7. Analyst's Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: Rusfertide, Clinical Trial Description, 2023
Table 2: Rusfertide, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: Rusfertide's pricing and cost Assumptions
Table 6: Rusfertide's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: Rusfertide Market Size in the US, in USD million (2020-2034)
Table 8: Rusfertide Market Size in Germany, in USD million (2020-2034)
Table 9: Rusfertide Market Size in France, in USD million (2020-2034)
Table 10: Rusfertide Market Size in Italy, in USD million (2020-2034)
Table 11: Rusfertide Market Size in Spain, in USD million (2020-2034)
Table 12: Rusfertide Market Size in the UK, in USD million (2020-2034)
Table 13: Rusfertide Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: Rusfertide's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: Rusfertide Market Size in the United States, USD million (2020-2034)
Figure 3: Rusfertide Market Size in Germany, USD million (2020-2034)
Figure 4: Rusfertide Market Size in France, USD million (2020-2034)
Figure 5: Rusfertide Market Size in Italy, USD million (2020-2034)
Figure 6: Rusfertide Market Size in Spain, USD million (2020-2034)
Figure 7: Rusfertide Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: Rusfertide Market Size in Japan, USD million (2020-2034)
For more information about this report visit https://www.researchandmarkets.com/r/piw0hd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.